AbbVie Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 11:14:29 2026-04-13 am EDT			5-day change	1st Jan Change
204.71 ^USD	-1.55%		-0.62%	-10.10%

08:58am	Earnings Season in Trump's Shadow
04:20am	Haisco Pharmaceutical Group Co., Ltd. Enters Exclusive License Agreement with AbbVie	CI

Published on 03/10/2026 at 12:35 pm EDT - Modified on 03/10/2026 at 02:05 pm EDT

S&P Capital IQ

Presenter Speech
David Risinger (Analysts)

So good morning, everyone. My name is Dave Risinger. I'm very pleased to host a couple of senior executives from AbbVie.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

08:58am	Earnings Season in Trump's Shadow
04:20am	Haisco Pharmaceutical Group Co., Ltd. Enters Exclusive License Agreement with AbbVie	CI
03:44am	Chinese Stocks Muted Amid Failed US-Iran Talks, Improved GDP Outlook	MT
03:41am	AbbVie Signs Global Pain Drug Licensing Deal With Haisco	MT
Apr. 12	Abbvie Showcases Late-Breaking Phase 2 Data for Mirvetuximab Soravtansine-Gynx in Platinum-Sensitive Ovarian Cancer	CI
Apr. 12	AbbVie Showcases Late-Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx in Platinum-Sensitive Ovarian Cancer	CI
Apr. 12	Haisco Pharmaceutical signs licensing agreement with AbbVie Group	RE
Apr. 10	AbbVie First-Quarter Earnings Unlikely to Lift Sentiment, RBC Says	MT
Apr. 10	Guggenheim Adjusts Price Target on AbbVie to $249 From $242, Maintains Buy Rating	MT
Apr. 09	Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says	MT
Apr. 09	Amneal Pharmaceuticals Launches Generic Lumigan Eye Drops	MT
Apr. 09	Wall Street Rethinks the Rally
Apr. 09	So far, so good
Apr. 08	AbbVie files lawsuit to address 'outdated' drug discount eligibility program	RE
Apr. 08	AbbVie Sues to Narrow Definition of Eligible Patients in US Drug Discount Program	MT